Cargando…
Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
Lenalidomide is an effective component of induction and maintenance therapy for multiple myeloma, though with a risk of secondary malignancies, including acute lymphoblastic leukemia (ALL). In contrast to therapy-related myeloid neoplasia, lenalidomide-associated lymphoblastic neoplasia remains poor...
Autores principales: | Geyer, Mark B., Shaffer, Brian C., Bhatnagar, Bhavana, Mims, Alice S., Klein, Victoria, Dilip, Deepika, Glass, Jacob L., Lozanski, Gerard, Hassoun, Hani, Landau, Heather, Zhang, Yanming, Xiao, Wenbin, Roshal, Mikhail, Park, Jae H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362546/ https://www.ncbi.nlm.nih.gov/pubmed/36827680 http://dx.doi.org/10.1182/bloodadvances.2022009212 |
Ejemplares similares
-
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021) -
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022) -
SIRPα(+) macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab
por: Marques-Piubelli, Mario L., et al.
Publicado: (2022) -
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial
por: Ferrero, Simone, et al.
Publicado: (2023) -
Toward prevention of childhood ALL by early-life immune training
por: Hauer, Julia, et al.
Publicado: (2021)